

18 September 2015

**EKF Diagnostics Holdings plc
("EKF", the "Company")**

New data published on PointMan™ molecular diagnostic technology

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces that two research posters supporting its PointMan™ molecular diagnostic technology have been delivered at key conferences.

On 8th September at the International Association for the Study of Lung Cancer's 16th World Conference on Lung Cancer meeting in Denver USA, Luecke et al from GILUPI GmbH and EKF Molecular presented a poster titled: An effective in vivo Liquid Biopsy tool for high yield isolation of circulating tumour cells. The researchers used EKF's PointMan KRAS DNA enrichment technology to analyse circulating tumour cells from blood samples taken from lung cancer patients using the GILUPI CellCollector®. The team concluded that the combination overcomes blood volume limitations of other CTC extraction approaches and mutations in isolated CTC DNA can be analysed using the PointMan technology. The Gilupi device allows CTC enumeration, molecular characterisation, and biomarker expression analysis, which could help guide treatment strategies and monitoring therapy efficacy.

PointMan also featured in a poster at the 9th Circulating Nucleic Acid in Plasma and Serum meeting in Berlin where Kimura et al from the Department of Respiratory Medicine, Kanazawa University Hospital, Japan, presented data on T790M DNA enrichment of specimens from a cohort of 52 lung cancer patients. T790M is an important biomarker as its presence indicates patients are becoming resistant to the drug regimen that is being used in the treatment of their late stage lung cancer. Being able to accurately, rapidly, cost effectively and non-invasively detect EGFR T790M early will assist in informing clinicians that a change in treatment is required. This poster expands on work previously presented at AACR in April and concludes that the PointMan assay is a useful and rapid technique for the detection of T790M in circulating DNA.

Julian Baines, CEO of EKF Diagnostics said: *"These posters presented at two of the world's most prestigious meetings of researchers and clinicians treating lung cancer confirm the utility of PointMan and its key role in the molecular analysis of circulating tumour cells and cancer DNA in liquid biopsies. The global incidence of lung cancer is estimated at 1.825M of which 85% are non-small cell lung cancer and relevant to the benefit that using PointMan will offer by way of indicating more targeted and effective treatment*

options for clinicians treating lung cancer in the future. The increasing body of scientific data that is being generated to support PointMan will be particularly important as we commercialise the technology following CE regulatory approval anticipated later this month."

In accordance with Rule 26.1 of the Takeover Code, a copy of this announcement will be published on the Company's website <http://www.ekfdiagnostics.com> by no later than 12 noon on 16 September 2015.

Enquiries:

EKF Diagnostics Holdings plc

David Evans, Executive Chairman
Julian Baines, CEO
Paul Foulger, CFO

Tel: 029 2071 0570

Mob: 07740 084 452
Mob: 07788 420 859
Mob: 07710 989 255

Panmure Gordon (UK) Limited

Robert Naylor (Corporate Finance)
Paul Fincham (Corporate Finance)

Tel: 020 7886 2500

Walbrook PR Limited

Mike Wort
Anna Dunphy

Tel: 020 7933 8780 or ekf@walbrookpr.com

Mob: 07900 608 002
Mob: 07876 741 001

This information is provided by RNS
The company news service from the London Stock Exchange

END

NRALRMATMBABBAA admin New data published on PointMan 23320691 A Fri, 09/18/2015 - 07:00
Company Announcement - General EKF